Results of the Complete Review on Targeted Therapies for Advanced Urothelial Carcinoma

María Natalia Gandur Quiroga shared on X:

” Results and Main Messages of the Complete Review on Targeted Therapies for Advanced Urothelial Carcinoma

• Bladder Cancer (BC): 10th most common worldwide. Advanced urothelial carcinoma (aUC) has poor outcomes and limited survival rates
• Current Treatments: Chemotherapy and immunotherapy show moderate efficacy; need for new therapies.
• Erdafitinib: Only FDA-approved targeted therapy for aUC. Median overall survival improved to 12.1 months vs. 7.8 months with chemotherapy. PFS was 5.6 months vs. 2.7 months. ORR: 46% vs. 12%.
• FGFR Inhibitors: Rogaratinib, Pemigatinib, Infigratinib, Futibatinib show promise in FGFR mutation.
• ErbB inhibitors: Afatinib, Cetuximab and others target EGFR and HER2 receptors, showing varying levels of efficacy.
• Combination Therapies: FGFR inhibitors combined with immune checkpoint inhibitors (ICIs) or other targeted therapies show greater efficacy.
• VEGF Pathway Inhibitors: Bevacizumab, Ramucirumab and others seek to block angiogenesis, crucial for tumor growth.
• Multitargeted TKIs: Dovitinib, Anlotinib, Cabozantinib target multiple pathways, offering broader treatment potential.”

Source: María Natalia Gandur Quiroga/X

Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina.

She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors.  She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.